CDX2 and cancer: Included studies were divided into two subgroups according to the cancer types, CDX2 expression was not associated with the chemotherapeutic effects in solid malignancies, no matter whether the cancer was colorectal (OR: 0.78, 95%CI: [0.33,1.82], P < 0.56, I2 = 83%) or ovarian (OR: 1.76, 95%CI: [0.91, 3.44], P < 0.09) (Figure 9).